Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.

Yung  Lyou

No Relationships to Disclose

Petros  Grivas

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen

Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)

Jonathan E.  Rosenberg

Stock and Other Ownership Interests  - Illumina

Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico

Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)

Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche

Jean H.  Hoffman-Censits

No Relationships to Disclose

David I.  Quinn

Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Seagen

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Seagen; US Biotest

Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche

(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest

Daniel Peter  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Expert Testimony - Celgene; sanofi

Matt D.  Galsky

Stock and Other Ownership Interests  - Rappta Therapeutics

Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)

Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792

Ulka N.  Vaishampayan

Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer

Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi

Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer

Ugo  De Giorgi

Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Pfizer; Sanofi

Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Pfizer

Sumati  Gupta

Stock and Other Ownership Interests  - Salarius Pharmaceuticals (I)

Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Viralytics (Inst)

Howard A.  Burris III

Employment - HCA Healthcare

Leadership - HCA Healthcare

Stock and Other Ownership Interests  - HCA Healthcare

Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst)

Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kyocera (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Novartis (Inst)

(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo (Inst); Pfizer (Inst)

Jessica  Rearden

Employment - Merck (I); QED Therapeutics

Stock and Other Ownership Interests  - Merck (I)

Corina  Andresen

Employment - QED Therapeutics

Stock and Other Ownership Interests  - QED Therapeutics

Honoraria - QED Therapeutics

Travel, Accommodations, Expenses - QED Therapeutics

Hao  Wang

Employment - QED Therapeutics

Siamak  Daneshmand

Stock and Other Ownership Interests  - Taris

Honoraria - Aduro Biotech; Allergan (I); Bristol-Myers Squibb; Ferring; Janssen; Johnson & Johnson; Nucleix; Olympus; pacific edge; Photocure; QED Therapeutics; Seagen; Spectrum Pharmaceuticals

Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris

Research Funding - Photocure

Travel, Accommodations, Expenses - Photocure

Dean F.  Bajorin

Honoraria - Merck Sharp & Dohme

Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma

Sumanta K.  Pal

Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer

Research Funding - Medivation